170 336

Cited 0 times in

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

DC Field Value Language
dc.contributor.author이민영-
dc.contributor.author차봉수-
dc.date.accessioned2021-12-28T16:52:45Z-
dc.date.available2021-12-28T16:52:45Z-
dc.date.issued2021-05-
dc.identifier.issn2233-6079-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/186832-
dc.description.abstractType 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor γ. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Diabetes Association-
dc.relation.isPartOfDIABETES & METABOLISM JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHDiabetes Mellitus, Type 2* / drug therapy-
dc.subject.MESHHumans-
dc.subject.MESHHypoglycemic Agents / adverse effects-
dc.subject.MESHPyrimidines-
dc.subject.MESHThiazolidinediones* / adverse effects-
dc.titleLobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJaehyun Bae-
dc.contributor.googleauthorTaegyun Park-
dc.contributor.googleauthorHyeyoung Kim-
dc.contributor.googleauthorMinyoung Lee-
dc.contributor.googleauthorBong-Soo Cha-
dc.identifier.doi10.4093/dmj.2020.0272-
dc.contributor.localIdA05491-
dc.contributor.localIdA03996-
dc.relation.journalcodeJ00720-
dc.identifier.eissn2233-6087-
dc.identifier.pmid33866775-
dc.subject.keywordDiabetes mellitus , type 2-
dc.subject.keywordLobeglitazone-
dc.subject.keywordThiazolidinediones-
dc.contributor.alternativeNameLee, Minyoung-
dc.contributor.affiliatedAuthor이민영-
dc.contributor.affiliatedAuthor차봉수-
dc.citation.volume45-
dc.citation.number3-
dc.citation.startPage326-
dc.citation.endPage336-
dc.identifier.bibliographicCitationDIABETES & METABOLISM JOURNAL, Vol.45(3) : 326-336, 2021-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.